PHILADELPHIA Frank L. Meyskens, Jr., M.D., one of the "fathers" of the field of cancer chemoprevention, has been selected to receive the seventh annual American Association for Cancer Research (AACR)-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research.
The award is given annually to a scientist for seminal contributions to the field of cancer prevention research in basic, translational, clinical, epidemiological or behavioral science.
Meyskens, Professor of Medicine and Biological Chemistry and Director of the Chao Family Comprehensive Cancer Center, and Associate Vice Chancellor of Health Sciences at the College of Health Sciences University of California, Irvine, is being honored for his many significant contributions to the field of cancer prevention and control.
His early work examined the translation of laboratory-based chemoprevention into clinical trials. Meyskens led the development of the combination of difluoromethylornithine (DFMO) plus Sulindac to dramatically reduce the risk of advanced colorectal adenoma recurrence.
Among his noteworthy accomplishments, Meyskens developed the topical all-trans-retinoic acid for chemoprevention of cervical intraepithelial neoplasia (CIN), the first of the cellular changes that may develop into cervical cancer in some women. Additionally, he promoted the idea that retinol could be used to affect chronic myelogenous leukemia (CML).
Meyskens has re-examined the scientific basis for the etiology of melanoma. Based on 15 years of detailed laboratory work, he proposed a new conceptual framework for melanoma etiology, prevention, and treatment. Most recently, he has provided a major, new insight into the non-UVR causation of melanoma with suggestions for potential preventive strategies.
Meyskens has published many seminal "thought" papers that have moved the field of cancer prevention forward. Perhaps, the most influential and important pap
|Contact: Megan J. Davies|
American Association for Cancer Research